H u ll ere r ('I (I /. : Neo pt erin cha nges d uring zidovud ine t rca tmcnt o r H I V -I infccti o n
( Rece ived M a rch 1990)
Introduction
In 1964, zidovudine (3 ' -azid o -3' -deoxy th ymidine . A Z T) wa s first sy nthesized (1) . This thymidine a ntagonist had antitum o ur and anti vira l acti vit y in vitro (2). In 199 5 zid ov udin e was show n to inhibit in vitro replicat io n (3 ) of human immunod eficiency vi ru s type 1 (HI V-1). Trea tment with zid ovudine induced significant clinical and immunological improvement in pati ents with AIDS a nd AIDS rela ted complex (4) . N eo pterin concent rati o ns were show n to be a significant predictor o f di sease progressio n in HI V-l seropositives. The predi cti ve inform a ti o n was independent fro m C D4 + T-cell co unts (5 -7) . Therefo re, we were inte res ted w hether neopterin co ncentrati o ns were influ enced by trea tment with zid ovudine of pa tients wi t h HI V-1 infecti o n .
Methods
Wc examined urin a ry neopterin concentrat io ns b y HPLC (8) in 14 HIV-l sero positi ves (11 ma le. 3 fem a le): 8 hom osex ua l men. 2 bi sex ual m en. 1 female intraveno us dru g a ddict . 1 m a le hom osex ua l intravenou s drug a ddict a nd 2 heterosex ual wo men. Thc age ra nge was 26 -53 yr. A ll underwent o ra l treatme nt with zidovudine due to ad vanced HIV -1 disease (m edi a n dose: 1200 m g/day) . U rines were co ll ected befo re treatment a nd preferentiall y eve ry three m o n ths during thera p y. U rin a ry neo pterin co ncentrati o ns we re related to urinary c rea tinine leve ls to account fo r ph ys io logical vari a tions of urine d ensities. U rina ry neo pterin conce ntra ti o ns significa ntly decreased durin g treatment co mpared to pretreatment le ve ls (Z = 2.5 7, P = 0.01 ; Wilco xon si gned rank test).
N o patient d ro pped within the no rm a l rnage o f health y sero nega ti ve co ntro ls. Nine o f 14 patients showed a d eclin e, w hich wa s greater th a n 20 % durin g th e first 6 m o nths of thera p y compared to pretrea tment level s (fi g . 1). One pa tient presented with increasing neo pterin concentra ti o ns (g rea ter than 20 % co mpa red to baseline) durin g the who le period o f th era p y_ There was a signi fi ca nt relati o nship betwee n th e decline of neo pterin co nce ntrations durin g therapy in rela tionshi p to the pretreatment level:
Neopterin d uring therapy = 0.441 x Neo pterin befo re th erapy + 191 (P = 0. ( 14) T he decrease of neopterin was independ en t from d ose a nd duration o f therapy (P < 0.1). altho ugh the m ajo rit y of pat ients showed sli ghtl y in creased neopterin leve ls durin g co ntinued thera p y. Ho wever, even after 18 m o nth s of therapy 3 o f 4 patients fo llo wed had nco pterin co nce ntration s which were still more tha n 20°/r, below th e pretreatment levels (F igure 1). 9 (51.7 -98.8) Neopterin changes during therapy were closely associated with the clinical presentation of patients. Decline of neopterin levels was always accompanied by clinical improvement. In the majority of patients declining neopterin levels were paralleled by increasing CD4+ T-cell counts (data not shown).
Discussion
During zidovudine therapy most of our HIV -1 seropositiv patients presented with declining neopterin concentrations compared to pretreatment levels. The neopterin changes reflected the beneficial effects of therapy on the course of HIV-1 related complications. However, none of the patients dropped into the normal range.
The decline of neopterin concentrations 111 our patients indicates that zidovudine therapy reduces the degree of chronic immune stimulation in patients, because large amounts of neopterin are released by macrophagcs on stimulation with interferon-gamma (9) . One of our patients showed continuously rising neopterin concentrations during treatment. Thus, zi-I'teridines Vol. 2 N o.2 dovudine is unlikely to directly inhibit neopterin production by macrophages.
Neopterin concentrations rise early in the course of HIV-l infection (9) and correlate to the replicative capacity of HIV-l isolates in vitro (10) . Since neopterin concentrations did not normalize in our patients treated with zidovudine it is likely that HIV-1 continues to replicate, albeit on a lower level. Recently it was shown that treatment with zidovudine rarely if ever eradicates H IV -1 from blood (11).
Certainly, zidovudine therapy reduces reproduction of virus, and therefore, immune stimulation by HIV-1 expressing cells ceases. On the other hand zidovudine could directly interfere with Iymphokine cascades during immune activation . Further studies have to be done to exclude the latter possibility. In conclusion, neopterin appears to be a sensitive marker during treatment of HIV -1 infection which provides useful information on the immunological status of the patients.
